Story perspectives

FDA Warns Firms Selling Unapproved Weight-Loss Drug Retatrutide

10/15/2025

50 4

Summary

Story summary

The U.S. Food and Drug Administration warned six companies for selling retatrutide, an unlicensed weight-loss drug in trials.
The FDA said the firms violated federal law by marketing the unapproved drug without supervision.
Social media influencers have driven interest in retatrutide.
Experts warn that purchasing the drug online poses risks of counterfeit or contaminated products.
Five of the six firms continue to sell retatrutide, priced from $99.99 to $1,025.

1 of 1

Story summary

The U.S. Food and Drug Administration warned six companies for selling retatrutide, an unlicensed weight-loss drug in trials.
The FDA said the firms violated federal law by marketing the unapproved drug without supervision.
Social media influencers have driven interest in retatrutide.
Experts warn that purchasing the drug online poses risks of counterfeit or contaminated products.
Five of the six firms continue to sell retatrutide, priced from $99.99 to $1,025.